BCL2L1 and cancer: For targeting these dormant cancer cells, a recent literature reported that down-regulating the Bcl-XL/Bcl-2 pathway in multinucleated colon carcinoma cells (HCT116) results in the rapid death of multinucleated giant cells through the treatment of ABT-263 (a small-molecule inhibitor of Bcl-X, Bcl-2 and Bcl-w) [36].